Theory Paper IDrNB Cardiology – Theory Notes
PHARMACOKINETICS AND PHARMACODYNAMICS: CARDIOVASCULAR APPLICATIONS
IINTRODUCTION AND CORE DEFINITIONS
- Pharmacokinetics (PK — “What the Body Does to the Drug”): Quantitative characterization of the time course of drug Absorption, Distribution, Metabolism (Biotransformation), and Excretion (ADME), governed by four primary mathematical parameters: Bioavailability (F), Volume of Distribution (Vd), Clearance (CL), and Elimination Half-Life (t1/2 = [0.693 x Vd] / CL).
- Pharmacodynamics (PD — “What the Drug Does to the Body”): The biochemical, cellular, and physiological effects of a drug at its molecular target (cardiac ion channels, G-protein-coupled receptors, enzymes, or transport pumps), characterized by receptor affinity, potency (EC50), maximal efficacy (Emax), therapeutic index, and hysteresis.
IIPHARMACOKINETIC (PK) PRINCIPLES APPLIED TO CARDIOVASCULAR DRUGS
- Absorption and Oral Bioavailability (F) — Loop Diuretics in Heart Failure:
- Clinical Application: Oral Furosemide has highly erratic and variable bioavailability (10 to 90 percent, mean ~50 percent), which is further impaired in acute decompensated right heart failure due to splanchnic venous congestion and intestinal mucosal edema (prolonging time to peak concentration without food). In contrast, Torsemide and Bumetanide possess predictable, rapid, high oral bioavailability (80 to 90 percent), making them superior for oral maintenance in congestive heart failure.
- Volume of Distribution (Vd = Dose / Plasma Concentration C0) and Loading Doses:
- Amiodarone (Massive Vd): Amiodarone is extremely lipophilic with a colossal apparent Volume of Distribution (~60 L/kg, or 4,000 to 5,000 Liters in a 70-kg adult) and an elimination half-life of 40 to 55 days (up to 100 days for its active metabolite desethylamiodarone). Because it sequesters rapidly into deep peripheral compartments (adipose tissue, liver, lung, skeletal muscle), achieving therapeutic myocardial concentrations requires a large cumulative loading dose of 8 to 10 grams (e.g., 400 mg TID for 1–2 weeks, then 400 mg OD) before stepping down to 100 to 200 mg daily.
- Digoxin in Skeletal Muscle vs. Renal Failure: Digoxin also has a large Vd (5 to 7 L/kg) because it binds extensively to Na+/K+-ATPase in skeletal muscle; in elderly, sarcopenic, or severe CKD patients, Vd is reduced by 30 to 50 percent, necessitating a lower loading dose (as well as a lower maintenance dose due to reduced renal clearance).
- Hepatic Biotransformation (First-Pass Metabolism, Prodrugs, and Active Metabolites):
- High First-Pass Extraction: Oral Propranolol, Metoprolol, Verapamil, and Nitroglycerin undergo extensive hepatic first-pass metabolism, which is why intravenous doses of Propranolol (1 to 5 mg) or Verapamil (5 to 10 mg) are an order of magnitude smaller than oral doses (40 to 160 mg).
- Prodrugs Requiring Bioactivation: Clopidogrel (activated via CYP2C19; impaired in about half of Indians, who carry 2/3 LoF alleles), Prasugrel** (rapid esterase + single CYP step, unaffected by CYP2C19 polymorphisms), Enalapril/Ramipril/Perindopril (esterase hydrolysis to “-prilat”; only Lisinopril and Captopril are active parent ACE inhibitors), Candesartan cilexetil (prodrug), and Losartan (converted to its more potent active metabolite EXP-3174).
- Active Metabolites with Dissociated Kinetics: Procainamide (Na+ channel blocker, Class IA) is acetylated via hepatic NAT2 into N-Acetylprocainamide (NAPA), an active metabolite that lacks Na+ channel activity and acts purely as a Class III K+ channel (IKr) blocker; in renal failure, NAPA accumulates and precipitates Torsades de Pointes.
- Renal vs. Hepatic Clearance (CL) — The DOAC Spectrum:
- Renal Clearance Hierarchy Among DOACs: Dabigatran (~80 percent renal clearance) > Edoxaban (~50 percent renal) > Rivaroxaban (~33 percent unchanged renal) > Apixaban (~27 percent renal). Consequently, Dabigatran is strictly contraindicated when CrCl is less than 30 mL/min, whereas Apixaban has the lowest renal dependence and safest bleeding profile in advanced CKD.
- Ultra-Short Context-Sensitive Half-Life: Esmolol (hydrolyzed by red blood cell cytosol esterases, t1/2 = 9 minutes), Clevidipine (plasma esterases, t1/2 = 1 minute), and Adenosine (endothelial/erythrocyte uptake and adenosine deaminase, t1/2 < 10 seconds) allow rapid titratability unaffected by hepatic or renal failure.
| Cardiovascular Drug | Key Pharmacokinetic (PK) Feature | Key Pharmacodynamic (PD) Feature | High-Yield Clinical Implication |
|---|---|---|---|
| Clopidogrel | Inactive Prodrug; 85% inactivated by CES1; 15% requires 2-step CYP2C19 oxidation | Irreversible covalent binding to platelet P2Y12 receptor for lifespan of platelet (7–10 d) | Slow onset (2–6 h); high resistance in CYP2C192/3; hold 5 days before CABG |
| Ticagrelor | Direct-acting parent drug (+ active CYP3A4 metabolite AR-C124910XX) | Reversible, allosteric non-competitive P2Y12 antagonist (+ ENT1 adenosine reuptake block) | Rapid onset (30 min); unaffected by CYP2C19; causes adenosine-mediated dyspnea/ventricular pauses; hold 3 days before surgery |
| Amiodarone | Huge Vd (~60 L/kg); t1/2 = 40–55 days; inhibits CYP2C9, CYP2D6, CYP3A4, and P-gp | Multichannel blocker (Class III IKr/IKs + Class I INa + Class II beta + Class IV ICa-L) | Requires 8–10 g loading dose; low TdP risk despite QTc prolongation (reduces transmural dispersion) |
| Digoxin | Large skeletal muscle Vd; cleared unchanged by renal GFR + P-gp tubular secretion (t1/2 = 36–48 h) | Inhibits Na+/K+-ATPase -> raises intracellular Na+ -> reverses NCX -> raises SR Ca2+ + vagotonic effect | Narrow therapeutic index (0.5–0.9 ng/mL in HF); hypokalemia allosterically increases Na+/K+-ATPase binding -> toxicity at normal levels |
| Loop Diuretics (Furosemide) | 95%+ albumin bound; secreted into proximal tubule via OAT1/OAT3 | Inhibits luminal NKCC2 cotransporter in thick ascending limb of Loop of Henle | Steep Sigmoidal (“Threshold & Ceiling”) Dose-Response Curve: doubling dose is required in HF/CKD to reach tubular threshold |
IIIPHARMACODYNAMIC (PD) PRINCIPLES IN CARDIOLOGY
- Potency vs. Maximal Efficacy & The Loop Diuretic “Threshold” Curve:
- Potency vs. Efficacy: Bumetanide (1 mg) = Torsemide (20 mg) = Furosemide (40 mg oral / 20 mg IV) differ in potency (milligram dose required), but all three loop diuretics share identical maximal natriuretic efficacy (Emax: excreting up to 20 to 25 percent of filtered sodium)—which is far superior to the maximal efficacy of Thiazide diuretics (Emax: 5 percent of filtered sodium).
- Steep Sigmoidal Dose-Response (“Threshold Effect”): Loop diuretics act from the luminal side of the nephron and exhibit a steep logarithmic dose-response curve; in heart failure or CKD, reduced renal blood flow and organic acid competition shift this curve to the right—meaning giving sub-threshold doses (e.g., 20 mg twice daily) produces zero diuresis, whereas doubling the single bolus dose to exceed the tubular threshold achieves brisk natriuresis.
- Use-Dependence vs. Reverse Use-Dependence of Antiarrhythmic Ion Channel Blockers:
- Use-Dependence (Fast Heart Rates): Class IC (Flecainide, Propafenone) and Class IA sodium channel blockers bind preferentially to open/inactivated Na+ channels and dissociate slowly (Flecainide has the slowest unbinding kinetics); consequently, QRS widening and proarrhythmia increase markedly during tachycardia (exercise or rapid atrial flutter).
- Reverse Use-Dependence (Slow Heart Rates): Class III IKr blockers (Sotalol, Dofetilide, Ibutilide) prolong action potential duration and the QT interval most markedly at slow heart rates (bradycardia or post-conversion pauses)—which is why Torsades de Pointes classically initiates after a “short-long-short” pause sequence.
- Narrow Therapeutic Index and Electrolyte PD Modification (Digoxin): In the DIG Trial post-hoc analysis, serum digoxin concentrations of 0.5 to 0.9 ng/mL reduced HF hospitalizations, whereas levels 1.2 ng/mL or greater increased mortality. Because Extracellular Potassium (K+) competes with Digoxin for the same binding site on the alpha-subunit of the sarcolemmal Na+/K+-ATPase pump, hypokalemia dramatically increases Digoxin binding and precipitates fatal toxicity (bidirectional VT, paroxysmal atrial tachycardia with 2:1 AV block) even when serum digoxin concentration is within the “normal” laboratory range.
- Receptor Desensitization, Down-Regulation, and Pharmacodynamic Tolerance:
- Nitrate Tolerance: Continuous 24-hour exposure to organic Nitrates depletes vascular sulfhydryl groups, inhibits mitochondrial aldehyde dehydrogenase (ALDH-2), and generates superoxide (peroxynitrite) that uncouples eNOS, causing rapid tachyphylaxis within 24 to 48 hours; prevented by providing a mandatory 10-to-14-hour daily nitrate-free interval.
- Beta-1 Receptor Up-Regulation in HFrEF: Chronic sympathetic catecholamine bombardment in HFrEF activates G-protein-coupled receptor kinase-2 (GRK2 / beta-ARK1) and beta-arrestin, causing selective down-regulation (by 50 to 60 percent) and uncoupling of myocardial Beta-1 receptors; chronic Beta-Blocker therapy causes an initial transient negative inotropic dip followed over 3 to 6 months by Beta-1 receptor resensitization/up-regulation and improved ejection fraction.
Key references
- Libby P, Bonow RO, Mann DL, Tomaselli GF, Bhatt DL, Solomon SD: Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 12th Ed., Elsevier, 2022.
- Ellison DH, Felker GM: Diuretic Treatment in Heart Failure, New England Journal of Medicine, 2017.
- Roden DM: Drug-Induced Prolongation of the QT Interval, New England Journal of Medicine, 2004.
meritmedscript.comDr. Sidhartha Mullapudi
